Upper Respiratory Tract Infection Treatment Market - Global Industry Analysis

Upper Respiratory Tract Infection Treatment Market - By Distribution Channel (Retail Pharmacies, Online Sales, And Hospital Pharmacies), By Treatment (Drug Treatment (NSAID, Antibiotics, And Others) And By Topical Treatment (Nasal Decongestant, Cough Suppressant, And Others)), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025

Published Date: 01-Feb-2021 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-1720 Status : Published

The global Upper Respiratory Tract Infection Treatment market, which was estimated at about 36.94 (USD Billion) in 2018 and is predicted to accrue earnings worth 58.99 (USD Billion) by 2025, is set to record a CAGR of nearly about 6.3% over 2019-2025.

Description

Global Upper Respiratory Tract Infection Treatment Market Size

The global Upper Respiratory Tract Infection Treatment market, which was estimated at about 36.94 (USD Billion) in 2018 and is predicted to accrue earnings worth 58.99 (USD Billion) by 2025, is set to record a CAGR of nearly about 6.3% over 2019-2025. The report offers a valuation and analysis of the Upper Respiratory Tract Infection Treatment market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on value (USD Billion).

Upper Respiratory Tract Infection Treatment Market: Overview

Upper respiratory tract infection is an illness that is caused by various viruses & bacteria. Myriad kinds of upper respiratory tract infections include acute bronchitis, flu, laryngitis, common cold, pharyngitis, sinusitis, sore throat, nasal obstruction, tonsillitis, otitis media, and respiratory distress syndrome. Furthermore, symptoms of upper respiratory tract infection include headache, low-grade fever, malaise, sinus pain, running nose, myalgia, breath shortness, nausea, body ache, cough, vomiting, conjunctivitis, sneezing, and diarrhea. Apparently, upper respiratory tract infection can be treated through decongestants, ibuprofen, guaifenesin, prednisone, diphenhydramine, and codeine. Moreover, Decongestants and antihistamine medicine are used in combination for restricting cough, nasal congestion, and various other symptoms in adult population.  

As per NIH researchers, upper respiratory tract infection is defined as upper airway irritation & swelling due to cough without being associated with pneumonia, COPD, chronic bronchitis, and emphysema.

Upper Respiratory Tract Infection Treatment Market: Growth Drivers

Surge in the cases of respiratory ailments, technological breakthroughs in medicine developments, and easy access to generic medicines will steer the expansion of upper respiratory tract infection treatment industry over the years ahead. Apart from inoculation, antiviral chemoprophylaxis can also prevent flue and is also considered as adjunct to inoculation in particular cases. It is also used when there is unavailability of vaccines or in the condition when inoculation cannot be done.

For instance, antiviral chemoprophylaxis is given to those persons suffering from influenza

(1) who fall in high risk zone for inoculation as a result of contraindication,

(2) those individuals who when vaccinated do not provide adequate immune response,

(3) for high-risk individuals who are constantly exposed to flue, and

(4) for controlling spread of disease in high-risk individuals across various institutions.

All these aforementioned aspects are projected to create lucrative growth avenues for upper respiratory tract treatment infection market over the years ahead.

Furthermore, antiviral therapy for flu assist in reducing time of flu symptoms, reduces the duration of stay at hospitals, and helps in minimizing the complication risks. This, in turn, will proliferate the growth of upper respiratory tract infection treatment market over the years to come. As per the evidence-based research made by Cochrane, Vitamin C, which is utilized as routine prophylaxis at nearly 0.2 grams doses for treating common cold symptoms, has demonstrated modest & constant effect on common cold in adults as well as children. This will support the expansion of upper respiratory tract infection treatment industry over the years ahead.  

Apparently, the common bacterial agents that cause sinusitis include S. Pneumonia, H. Influenza, S. Aureus, S. Pyogenes, and M. Catarrhalis. Moreover, amoxicillin is an antibacterial drug that is used for treating sinusitis. The other medicine used for treating sinusitis is cephalexin when the disease is chronic or recurs. All these aforementioned factors will contribute immensely towards upper respiratory tract infection treatment market size in the foreseeable future.

North America To Make Lucrative Contributions Towards Overall Market Revenue By 2025

The expansion of upper respiratory tract infection treatment industry in North America over the forecast timespan is attributed to surge in the incidences of upper respiratory tract infections across the U.S. Apart from this, increase in the home visits by physicians due to upper respiratory tract infections and escalating demand for over the counter medicines to treat these infections will steer the expansion of upper respiratory tract infection treatment market in North America over the ensuing years.

Competitive Landscape

The key players profiled in the study and influencing the growth of upper respiratory tract infection treatment industry are Pfizer Inc., Collegium Pharmaceutical, Inc., Merck & Co., Inc., Alcon, Inc., Sandoz, Inc., GlaxoSmithKline plc, Verona Pharma Plc, Teva Pharmaceuticals, and Hospira, Inc.

The global upper respiratory tract infection treatment market is segmented as follows:

By Distribution Channel

  • Retail Pharmacies
  • Online Sales
  • Hospital Pharmacies

By Treatment

  • Topical treatment
    • Cough Suppressant
    • Nasal Decongestant
    • Others
  • Drug treatment
    • NSAID
    • Antibiotics
    • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Upper Respiratory Tract Treatment Infection Market, 2015–2025 (USD Billion)
    • 2.2. Upper Respiratory Tract Treatment Infection Market: Snapshot
  • Chapter 3. Global Upper Respiratory Tract Treatment Infection Market– Industry Analysis
    • 3.1. Upper Respiratory Tract Treatment Infection Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Antiviral therapy for flu assist in reducing time of flu symptoms, reduces the duration of stay at hospitals, and helps in minimizing the complication risks. This, in turn, will pruliferate the growth of upper respiratory tract infection treatment market over the years to come.
      • 3.2.2. The common bacterial agents that cause sinusitis include S. Pneumonia, H. Influenza, S. Aureus, S. Pyogenes, and M. Catarrhalis. Moreover, amoxicillin is an antibacterial drug that is used for treating sinusitis. The other medicine used for treating sinusitis is cephalexin when the disease is chronic or recurs. All these aforementioned factors will contribute immensely towards upper respiratory tract infection treatment market size in the foreseeable future.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Treatment
      • 3.4.2. Market attractiveness analysis By Distribution Channel
  • Chapter 4. Global Upper Respiratory Tract Treatment Infection Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Upper Respiratory Tract Treatment Infection Market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Upper Respiratory Tract Treatment Infection Market– Treatment Analysis
    • 5.1. Global Upper Respiratory Tract Treatment Infection Market overview: By Treatment
      • 5.1.1. Global Upper Respiratory Tract Treatment Infection Market share, By Treatment, 2018 and 2025
    • 5.2. Topical Treatment
      • 5.2.1. Global Upper Respiratory Tract Treatment Infection Market By Topical Treatment, 2015–2025 (USD Billion)
    • 5.3. Drug Treatment
      • 5.3.1. Global Upper Respiratory Tract Treatment Infection Market By Drug Treatment, 2015–2025 (USD Billion)
  • Chapter 6. Global Upper Respiratory Tract Treatment Infection Market– Distribution Channel Analysis
    • 6.1. Global Upper Respiratory Tract Treatment Infection Market overview: By Distribution Channel
      • 6.1.1. Global Upper Respiratory Tract Treatment Infection Market share, By Distribution Channel , 2018 and 2025
    • 6.2. Hospital Pharmacies
      • 6.2.1. Global Upper Respiratory Tract Treatment Infection Market By Hospital Pharmacies, 2015–2025 (USD Billion)
    • 6.3. Online Sales
      • 6.3.1. Global Upper Respiratory Tract Treatment Infection Market By Online Sales, 2015–2025 (USD Billion)
    • 6.4. Retail Pharmacies
      • 6.4.1. Global Upper Respiratory Tract Treatment Infection Market By Retail Pharmacies, 2015–2025 (USD Billion)
  • Chapter 7. Company Profiles
    • 7.1. Alcon, Inc.
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. GlaxoSmithKline plc
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Merck & Co., Inc.
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Verona Pharma Plc
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Cullegium Pharmaceutical, Inc.
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. Pfizer Inc.
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. Teva Pharmaceuticals
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Sandoz, Inc.
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Hospira, Inc.
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development

Table Of Figures

List of Figures

1. Market research Type
2. Market research methodology
3. Global Upper Respiratory Tract Treatment Infection Market, 2015–2025 (USD Billion)
4. Porter’s Five Forces Analysis
5. Global Upper Respiratory Tract Treatment Infection Market attractiveness, By Treatment  
6. Global Upper Respiratory Tract Treatment Infection Market attractiveness, By Distribution Channel  
7. Global Upper Respiratory Tract Treatment Infection Market share by Treatment ,2018 and 2025 (USD Billion)
8. Global Upper Respiratory Tract Treatment Infection Market By Topical Treatment ,2015–2025 (USD Billion)
9. Global Upper Respiratory Tract Treatment Infection Market By Drug Treatment ,2015–2025 (USD Billion)
10. Global Upper Respiratory Tract Treatment Infection Market share by Distribution Channel, 2018 and 2025 (USD Billion)
11. Global Upper Respiratory Tract Treatment Infection Market By Hospital Pharmacies,2015–2025 (USD Billion)
12. Global Upper Respiratory Tract Treatment Infection Market By Online Sales ,2015–2025 (USD Billion)
13. Global Upper Respiratory Tract Treatment Infection Market By Retail Pharmacies ,2015–2025 (USD Billion)
14. Global Upper Respiratory Tract Treatment Infection Market share, by Region, 2018 and 2025
15. North America Upper Respiratory Tract Treatment Infection Market, 2015–2025 (USD Billion)
16. Europe Upper Respiratory Tract Treatment Infection Market, 2015–2025 (USD Billion)
17. Asia Pacific Upper Respiratory Tract Treatment Infection Market, 2015–2025 (USD Billion)
18. Latin America Upper Respiratory Tract Treatment Infection Market, 2015–2025 (USD Billion)
19. The Middle East and Africa Upper Respiratory Tract Treatment Infection Market, 2015–2025 (USD Billion)
 


Table Of Tables

List of Tables

1. Global Upper Respiratory Tract Treatment Infection Market: snapshot
2. Drivers of the Upper Respiratory Tract Treatment Infection Market: impact analysis
3. North America Upper Respiratory Tract Treatment Infection Market revenue, By Treatment   , 2015–2025 (USD Billion)
4. North America Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
5. The U.S. Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
6. The U.S. Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
7. Rest of North America Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
8. Rest of North America Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
9. Europe Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
10. Europe Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
11. UK Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
12. UK Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
13. France Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
14. France Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
15. Germany Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
16. Germany Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
17. Rest of Europe Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
18. Rest of Europe Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
19. Asia Pacific Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
20. Asia Pacific Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
21. China Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
22. China Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
23. Japan Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
24. Japan Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
25. India Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
26. India Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
27. Rest of Asia Pacific Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
28. Rest of Asia Pacific Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
29. Latin America Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
30. Latin America Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
31. Brazil Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
32. Brazil Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
33. Rest of Latin America Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
34. Rest of Latin America Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
35. The Middle East and Africa Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
36. The Middle East and Africa Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
37. Saudi Arabia Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
38. Saudi Arabia Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
39. South Africa Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
40. South Africa Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel  , 2015–2025 (USD Billion)
41. Rest of the Middle East & Africa Upper Respiratory Tract Treatment Infection Market revenue, By Treatment    , 2015–2025 (USD Billion)
42. Rest of the Middle East & Africa Upper Respiratory Tract Treatment Infection Market revenue, By Distribution Channel   , 2015–2025 (USD Billion)

 
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Surge in the cases of respiratory ailments, technological breakthroughs in medicine developments, and easy access to generic medicines will steer the expansion of upper respiratory tract infection treatment industry over the years ahead. Apart from inoculation, antiviral chemoprophylaxis can also prevent flue and is also considered as adjunct to inoculation in particular cases. It is also used when there is unavailability of vaccines or in the condition when inoculation cannot be done. For instance, antiviral chemoprophylaxis is given to those persons suffering from influenza (1) who fall in high risk zone for inoculation as a result of contraindication, (2) those individuals who when vaccinated do not provide adequate immune response, (3) for high-risk individuals who are constantly exposed to flue, and (4) for controlling spread of disease in high-risk individuals across various institutions. All these aforementioned aspects are projected to create lucrative growth avenues for upper respiratory tract treatment infection market over the years ahead.

According to Zion Market Research report, the global Upper Respiratory Tract Infection Treatment market, which was estimated at about 36.94 (USD Billion) in 2018 and is predicted to accrue earnings worth 58.99 (USD Billion) by 2025, is set to record a CAGR of nearly about 6.3% over 2019-2025.

North America is likely to make noteworthy contributions towards overall Upper Respiratory Tract Treatment Infection Market revenue over 2019-2025. The growth of the market in the region over estimated timespan can be ascribed to surge in the incidences of upper respiratory tract infections across the U.S. Apart from this, increase in the home visits by physicians due to upper respiratory tract infections and escalating demand for over the counter medicines to treat these infections will steer the expansion of upper respiratory tract infection treatment market in North America over the ensuing years.

The key players profiled in the report include Pfizer Inc., Collegium Pharmaceutical, Inc., Merck & Co., Inc., Alcon, Inc., Sandoz, Inc., GlaxoSmithKline plc, Verona Pharma Plc, Teva Pharmaceuticals, and Hospira, Inc.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed